Maryland Center for Multiple Sclerosis: Clinical Trials Open for Enrollment
Opportunities are available for individuals with Multiple Sclerosis to participate in several new clinical trials at the University of Maryland Center for Multiple Sclerosis. These studies are either currently enrolling or will be enrolling shortly. The studies vary in design, duration, criteria for eligibility, number of MRI scans, and other details. The following is a very brief summary of each study. You may obtain further information by calling Kerry Naunton, R.N., 410-328-1885 or Karen Callison, R.N., 410-328-7602 at the MS Center.
- The Pfizer trial is a study of a drug known as RN-168 in patients with multiple sclerosis. This trial is a Phase I study which means that it is tested in a small number of patients for the first time. The medication is injected under the skin into the fatty tissues of the abdomen. Subjects will receive either RN 168 or placebo. The study will last approximately 6 months. This medication is being tested as a possible new therapy to treat multiple sclerosis.
Investigator: Walter Royal, MD
Eligibility: This trial is designed for people 18-55 years of age who have multiple sclerosis.
Currently recruiting clinical trial opportunities are constantly changing. Please keep in touch if you are interested in trials!
For more information about the Maryland Center for Multiple Sclerosis, please call 410-328-5605.